GSK · Pharma and healthcare · one day
GSK (GSK): news on Friday 20 November 2026
News from the 24 hours to Friday morning, 20 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage mainly covered a second US approval for a lung cancer drug from the Nuvalent purchase and Japanese orphan drug status for velzatinib in GIST. Antibiotic manufacturing certification added to the positive tone, though one report noted a share price fall of 1.7%.
What drove it
- FDA lung cancer approval
- velzatinib orphan designation
- antibiotic manufacturing certification
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sat 14 Nov | +9.2 | 20 |
| Sun 15 Nov | +7.0 | 6 |
| Mon 16 Nov | +2.5 | 4 |
| Tue 17 Nov | +5.7 | 8 |
| Wed 18 Nov | +7.5 | 36 |
| Thu 19 Nov | 0.0 | 1 |
| Fri 20 Nov | +6.3 | 22 |
6 stories · 22 headlines · strongest first
Pharma and healthcare on 20 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Japan gives velzatinib orphan designation for GIST +5.88 headlines today · Japan has given GSK's velzatinib orphan drug status for gastrointestinal stromal tumours, and pivotal data are expected in 2027. | ||
| +6.3 | Designation plus a stated timeline for key trial data. | |
| +5.8 | Company's own announcement of Japanese orphan status. | |
| +5.8 | Japanese special status for a cancer drug candidate aids development. | |
| +5.8 | Rare-tumour drug receives favourable Japanese designation. | |
| +5.7 | Orphan status in Japan supports the GIST candidate. | |
| +5.7 | Japanese orphan status granted for GIST treatment. | |
| +5.7 | Japanese orphan designation for gastrointestinal tumour drug. | |
| +5.5 | Late-stage drug obtains rare-disease status in Japan. | |
| Nelkarmi receives US accelerated approval for ALK-positive lung cancer +9.44 headlines today · 26 in all, since 18 November · Commentary on the FDA lung cancer approval and its Nuvalent-derived origin and implications for the oncology pipeline. | ||
| +10.0 | Second US regulatory clearance for a lung cancer therapy gained through acquisition. | |
| +10.0 | Acquired company's drug gains another approval, validating the large purchase. | |
| +8.3 | Lung cancer approval strengthens oncology pipeline and savings outlook. | |
| +7.5 | Investor-focused look at benefits of the new approval. | |
| GSK share outlook and market commentary 0.04 headlines today · 11 in all, since 17 November · Technical analysis and market pieces discuss GSK's share price moves and setup. | ||
| −4.2 | Share price fell during the session. | |
| +0.8 | Generic market positioning commentary ahead of next trading day. | |
| −0.8 | Technical chart note describing sideways trading near support. | |
| +0.3 | Minor share price observation, essentially flat. | |
| GSK wins UPC injunction against Pfizer and BioNTech +6.03 headlines today · 13 in all, since 12 November · Articles looking at what lies ahead for BioNTech refer to a window of three months tied to GSK, and to an FDA voucher. | ||
| +0.8 | Focuses on BioNTech's timeline, with GSK as a named counterparty. | |
| +0.5 | BioNTech-focused timeline mentioning GSK window. | |
| +0.5 | BioNTech-centred piece, GSK only a named party with a deadline. | |
| GSK has its antibiotic production plants certified to the AMR standard +6.82 headlines today · GSK reported that all its antibiotic manufacturing sites are certified against an antimicrobial resistance standard. | ||
| +7.0 | All antibiotic plants meet an anti-resistance standard, helping reputation. | |
| +6.7 | Global certification for antibiotic production sites reflects well on GSK. | |
| ViiV Healthcare appoints HR business leader +0.71 headline today · 2 in all, since 15 November · Magnus Hibbert was promoted to a senior vice president HR role at GSK. | ||
| +0.8 | Routine senior HR appointment, little bearing on prospects. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.